{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:41:05Z","timestamp":1759452065006,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","issue":"46","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004083","name":"Ministry of Science ICT and Future Planning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004083","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Korea Ministry of Science and ICT","doi-asserted-by":"publisher","award":["2020M3A9I2108860","2022M3A9J21081348"],"award-info":[{"award-number":["2020M3A9I2108860","2022M3A9J21081348"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.vaccine.2023.10.008","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T15:12:06Z","timestamp":1696864326000},"page":"6842-6851","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Nonclinical safety assessment and immunogenicity of rVSVInd(GML)-mspSGtc vaccine for SARS-CoV-2 in rabbits"],"prefix":"10.1016","volume":"41","author":[{"given":"Heeseon","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min Seong","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Ah","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woojin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Bum","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na Hyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunsil","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4388-0952","authenticated-orcid":false,"given":"Hwa-Young","family":"Son","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8187-6837","authenticated-orcid":false,"given":"Kang-Hyun","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.10.008_b0005","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41579-022-00713-0","article-title":"SARS-CoV-2 pathogenesis","volume":"20","author":"Lamers","year":"2022","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2023.10.008_b0010","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1126\/science.abm8108","article-title":"The immunology and immunopathology of COVID-19","volume":"375","author":"Merad","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2023.10.008_b0015","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1126\/science.abn1755","article-title":"COVID-19 vaccination: the road ahead","volume":"375","author":"Altmann","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2023.10.008_b0020","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1001\/jama.2021.13443","article-title":"Myocarditis and pericarditis after vaccination for COVID-19","volume":"326","author":"Diaz","year":"2021","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.vaccine.2023.10.008_b0025","doi-asserted-by":"crossref","DOI":"10.1186\/s40001-022-00695-y","article-title":"Acute cardiac side effects after COVID-19 mRNA vaccination: a case series","volume":"27","author":"Freise","year":"2022","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.vaccine.2023.10.008_b0030","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00701-021-04860-w","article-title":"Cerebral venous sinus thrombosis 2 weeks after the first dose of mRNA SARS-CoV-2 vaccine","volume":"163","author":"Zakaria","year":"2021","journal-title":"Acta Neurochir"},{"key":"10.1016\/j.vaccine.2023.10.008_b0035","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.molmed.2022.04.007","article-title":"Adverse effects of COVID-19 mRNA vaccines: the Spike hypothesis","volume":"28","author":"Trougakos","year":"2022","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.vaccine.2023.10.008_b0040","article-title":"rVSV\u0394G-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire glycoprotein: Standardized template with key considerations for a risk\/benefit assessment","volume":"1","author":"Monath","year":"2019","journal-title":"Vaccine: X"},{"key":"10.1016\/j.vaccine.2023.10.008_b0045","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1038\/mt.2009.154","article-title":"Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus","volume":"17","author":"Bridle","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2023.10.008_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/imm.12829","article-title":"Novel viral vectors in infectious diseases","volume":"153","author":"Humphreys","year":"2018","journal-title":"Immunology"},{"key":"10.1016\/j.vaccine.2023.10.008_b0055","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-20228-7","article-title":"A single dose of recombinant VSV-\u0394G-spike vaccine provides protection against SARS-CoV-2 challenge","volume":"11","author":"Yahalom-Ronen","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2023.10.008_b0060","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2217\/fmb-2019-0237","article-title":"Safety, immunogenicity and risk\u2013benefit analysis of rVSV-\u0394G-ZEBOV-GP (V920) Ebola vaccine in Phase I-III clinical trials across regions","volume":"15","author":"Bache","year":"2020","journal-title":"Future Microbiol"},{"key":"10.1016\/j.vaccine.2023.10.008_b0065","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1473-3099(15)00154-1","article-title":"The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1\/2 trial","volume":"15","author":"Huttner","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2023.10.008_b0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010092","article-title":"A vesicular stomatitis virus-based prime-boost vaccination strategy induces potent and protective neutralizing antibodies against SARS-CoV-2","volume":"17","author":"Kim","year":"2021","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2023.10.008_b0075","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.yrtph.2017.07.010","article-title":"Implementation of Good Laboratory Practices (GLP) in basic scientific research: translating the concept beyond regulatory compliance","volume":"89","author":"Jena","year":"2017","journal-title":"Regul Toxicol Pharm"},{"key":"10.1016\/j.vaccine.2023.10.008_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111254","article-title":"Targets and strategies for vaccine development against SARS-CoV-2","volume":"137","author":"Malik","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.vaccine.2023.10.008_b0085","unstructured":"MFDS (Republic of Korea). Ministry of Food and Drug Safety notification no. 2018-93. Good Laboratory Practice Regulations for Nonclinical Laboratory Studies; 2018."},{"key":"10.1016\/j.vaccine.2023.10.008_b0090","unstructured":"OECD, GLP \u201cOECD principles of good laboratory practice.\u201d Series on Principles of Good Laboratory Practice and Compliance Monitoring, No. 1; 1998 (ENV. MC\/CHEM (98) 17)."},{"key":"10.1016\/j.vaccine.2023.10.008_b0095","unstructured":"FDA, US Food and Drug Administration. Code of federal regulations title 21, part 58. Good Laboratory Practice Regulations for Nonclinical Laboratory Studies; 2020."},{"key":"10.1016\/j.vaccine.2023.10.008_b0100","unstructured":"World Health Organization (WHO). Guidelines on the nonclinical evaluation of vaccine adjuvants and adjuvanted vaccines. World Health Organization; 2013. p. 616\u201324."},{"key":"10.1016\/j.vaccine.2023.10.008_b0105","unstructured":"MFDS (Republic of Korea). Ministry of Food and Drug Safety Guideline on Nonclinical Evaluation of Biopharmaceuticals; 2014."},{"key":"10.1016\/j.vaccine.2023.10.008_b0110","unstructured":"MFDS (Republic of Korea). Ministry of Food and Drug Safety notification No. 2017-71 test guidelines for safety evaluation of drugs: annex 2 repeat dose toxicity study and annex 8 skin irritation study; 2017."},{"key":"10.1016\/j.vaccine.2023.10.008_b0115","unstructured":"Organization for Economic Cooperation and Development. Test No. 404: acute dermal irritation\/corrosion. OECD Publishing; 2015."},{"key":"10.1016\/j.vaccine.2023.10.008_b0120","article-title":"Production of native bispecific antibodies in rabbits","volume":"5","author":"Wang","year":"2010","journal-title":"PLoS One"},{"year":"2009","series-title":"Laboratory animal medicine","author":"Fox","key":"10.1016\/j.vaccine.2023.10.008_b0125"},{"key":"10.1016\/j.vaccine.2023.10.008_b0130","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/jat.3314","article-title":"Dose site reactions and related findings after vaccine administration in safety studies","volume":"36","author":"Baldrick","year":"2016","journal-title":"J Appl Toxicol"},{"key":"10.1016\/j.vaccine.2023.10.008_b0135","first-page":"143","article-title":"Types of acute phase reactants and their importance in vaccination","volume":"12","author":"Khalil","year":"2020","journal-title":"Biomed Rep"},{"key":"10.1016\/j.vaccine.2023.10.008_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-019-0132-6","article-title":"The how\u2019s and what\u2019s of vaccine reactogenicity","volume":"4","author":"Herv\u00e9","year":"2019","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2023.10.008_b0145","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2021.2002083","article-title":"A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson","volume":"18","author":"Patel","year":"2022","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"10.1016\/j.vaccine.2023.10.008_b0150","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01848-21","article-title":"Golden Syrian Hamsters as a model for revisiting the role of biological sex differences in SARS-CoV-2 infection","volume":"12","author":"Michita","year":"2021","journal-title":"MBio"},{"issue":"4","key":"10.1016\/j.vaccine.2023.10.008_b0155","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00974-21","article-title":"Sex differences in lung imaging and SARS-CoV-2 antibody responses in a COVID-19 golden Syrian hamster model","volume":"12","author":"Dhakal","year":"2021","journal-title":"MBio"},{"issue":"3","key":"10.1016\/j.vaccine.2023.10.008_b0160","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4103\/1995-7645.340567","article-title":"Sex differences in SARS-CoV-2 infections, anti-viral immunity and vaccine responses","volume":"15","author":"Mohanty","year":"2022","journal-title":"Asian Pac J Trop Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23011787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23011787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:31:46Z","timestamp":1759404706000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23011787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":32,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0264410X23011787"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.10.008","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonclinical safety assessment and immunogenicity of rVSVInd(GML)-mspSGtc vaccine for SARS-CoV-2 in rabbits","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}